Pfizer makes first-line case for Tukysa in breast cancer

Pfizer’s Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844